Idexx's Q3 adjusted EPS rose 12% to $2.79, beating the $2.68 consensus. Organic revenue grew 6%, driven by Companion Animal and Water segment gains. Live on Wednesday: Historic Summer Setup: 3 "Power ...
Cancer Dx Panel expansion and inVue Dx FNA cytology rollout advance veterinary cancer care, enabling comprehensive mast cell ...
A month has gone by since the last earnings report for Idexx Laboratories (IDXX). Shares have lost about 0.4% in that time frame, underperforming the S&P 500. But investors have to be wondering, will ...
IDEXX Laboratories continues to outperform the S&P 500, driven by strong recurring revenue and a robust customer ecosystem. IDXX delivered a double beat in Q3, with revenue up 13% and EPS up 21%, ...
ImageVue DR50 Plus introduces high-definition diagnostic imaging at the lowest dose of radiation, accelerating diagnosis and ...
IDEXX's business model relies on selling diagnostic equipment, consumables, veterinary software, and diagnostic imaging to generate recurring revenue. The company has experienced double-digit growth ...
Hosted on MSN
Idexx raises 2025 revenue outlook to $4.28B as inVue Dx placements surge and innovation momentum builds
Jonathan J. Mazelsky, CEO, highlighted, "IDEXX delivered a very strong quarter of performance as reflected in solid execution across all key drivers of our strategy." He emphasized rapid adoption of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results